Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142191 | 0.83 | ADRA2A (0.31) | NPC1RAB9A | |
| SCHEMBL6142180 | 0.70 | CYP3A4 (0.48) | NPC1RAB9A | |
| SCHEMBL6142174 | 0.70 | LMNA (0.39) | NPC1RAB9A | |
| SCHEMBL6142355 | 0.70 | NPC1 (0.38) | NPC1RAB9A | |
| SCHEMBL5544044 | 0.70 | ALDH1A1 (0.33) | NPC1RAB9A | |
| SCHEMBL8580366 | 0.70 | CYP3A4 (0.34) | — | |
| SCHEMBL7458773 | 0.69 | ALDH1A1 (0.35) | NPC1RAB9A | |
| SCHEMBL7206719 | 0.69 | ADRA2A (0.36) | NPC1RAB9A | |
| SCHEMBL6142522 | 0.69 | DPP4 (0.36) | NPC1RAB9A | |
| SCHEMBL21741609 | 0.68 | NPC1 (0.33) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | NPC1 2465/4885RAB9A 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.